DK1716119T3 - Analoger af benzoquinonholdige ansamyciner til behandling af cancer - Google Patents

Analoger af benzoquinonholdige ansamyciner til behandling af cancer

Info

Publication number
DK1716119T3
DK1716119T3 DK04817048.4T DK04817048T DK1716119T3 DK 1716119 T3 DK1716119 T3 DK 1716119T3 DK 04817048 T DK04817048 T DK 04817048T DK 1716119 T3 DK1716119 T3 DK 1716119T3
Authority
DK
Denmark
Prior art keywords
anamicycines
benzoquinon
analogs
cancer
treatment
Prior art date
Application number
DK04817048.4T
Other languages
Danish (da)
English (en)
Inventor
Julian Adams
Yun Gao
Evangelinos Asimina T Georges
Louis Grenier
Roger H Pak
James R Porter
James L Wright
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34744040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1716119(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Application granted granted Critical
Publication of DK1716119T3 publication Critical patent/DK1716119T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04817048.4T 2003-12-23 2004-12-23 Analoger af benzoquinonholdige ansamyciner til behandling af cancer DK1716119T3 (da)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US53208003P 2003-12-23 2003-12-23
US54014204P 2004-01-29 2004-01-29
US54738104P 2004-02-23 2004-02-23
US56171804P 2004-04-12 2004-04-12
US56756504P 2004-05-03 2004-05-03
US60628304P 2004-09-01 2004-09-01
US62628604P 2004-11-09 2004-11-09
US63285804P 2004-12-03 2004-12-03
PCT/US2004/043162 WO2005063714A1 (en) 2003-12-23 2004-12-23 Analogs of benzoquinone-containing ansamycins for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK1716119T3 true DK1716119T3 (da) 2013-06-10

Family

ID=34744040

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04817048.4T DK1716119T3 (da) 2003-12-23 2004-12-23 Analoger af benzoquinonholdige ansamyciner til behandling af cancer

Country Status (15)

Country Link
US (13) US7282493B2 (enExample)
EP (2) EP2492261B1 (enExample)
JP (2) JP4869077B2 (enExample)
KR (1) KR101154351B1 (enExample)
CN (1) CN102643233B (enExample)
AU (1) AU2004309395C1 (enExample)
BR (1) BRPI0418147A (enExample)
CA (1) CA2547343C (enExample)
DK (1) DK1716119T3 (enExample)
ES (1) ES2409351T3 (enExample)
IL (2) IL175911A (enExample)
NO (1) NO337933B1 (enExample)
PT (1) PT1716119E (enExample)
RU (1) RU2484086C9 (enExample)
WO (1) WO2005063714A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
EP2492261B1 (en) 2003-12-23 2015-02-18 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
JP2008519031A (ja) * 2004-11-02 2008-06-05 コンフォーマ・セラピューティクス・コーポレイション 慢性リンパ球性白血病を治療する方法および組成物
US10252088B2 (en) 2004-12-02 2019-04-09 Obagi Cosmeceuticals Llc Topical compositions and methods of manufacturing them in specifically treated steel vessels
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
US11457813B2 (en) 2005-03-29 2022-10-04 Martin W. Roche Method for detecting body parameters
EP1874296A4 (en) * 2005-04-29 2010-06-30 Kosan Biosciences Inc METHOD FOR THE TREATMENT OF SEVERAL MYELOMES USING 17-AAG OR 17-AG OR PRODRUGS OR ALL
GB0517886D0 (en) * 2005-09-02 2005-10-12 Biotica Tech Ltd Novel compounds
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070207992A1 (en) * 2006-02-21 2007-09-06 Board Of Trustees Of Michigan State University Geldanamycin derivatives and method of use thereof
GB0606548D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
ES2389740T3 (es) 2006-11-09 2012-10-31 Bristol-Myers Squibb Company Nuevos compuestos y procedimientos para su producción
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
CA2684211A1 (en) * 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
CA2687614C (en) * 2007-06-07 2013-04-30 Joyant Pharmaceuticals, Inc. Methods for preparing diazonamides
US8551964B2 (en) 2007-08-23 2013-10-08 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
EP2348845A4 (en) * 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc ANSAMYCIN HYDROQUINONE COMPOSITIONS
WO2010124283A2 (en) * 2009-04-24 2010-10-28 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
US20120108563A1 (en) * 2009-05-19 2012-05-03 Infinity Pharmaceuticals, Inc. Methods Of Treating Liposarcoma
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US9603829B2 (en) 2011-11-14 2017-03-28 The Regents Of The University Of Colorado, A Body Corporate HSP90 inhibitors with modified toxicity
WO2017048911A1 (en) * 2015-09-19 2017-03-23 Applied Materials, Inc. Surface-selective atomic layer deposition using hydrosilylation passivation
US10052304B2 (en) 2015-10-12 2018-08-21 University Of Iowa Research Foundation Compositions and methods for cancer therapy
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US123640A (en) 1872-02-13 Improvement in tab-plates of buckles
US120578A (en) 1871-11-07 Improvement in letter-boxes
US745718A (en) * 1903-04-25 1903-12-01 Owen Thomas Dougherty Weight-indicating sliding and spring support for vehicle-bodies.
GB210611A (en) * 1923-01-16 1924-02-07 Clarence Hancock Improved means of heating garden propagating frames, foster mothers and the like
US3595955A (en) 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
JPS5470299A (en) * 1977-11-14 1979-06-05 Takeda Chem Ind Ltd Production of maytansine derivative
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111B (en) * 1981-09-17 1985-11-06 Takeda Chemical Industries Ltd Macbecin derivatives and their production
JPS5874651A (ja) * 1981-09-17 1983-05-06 Takeda Chem Ind Ltd マクベシン誘導体およびその製造法
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
NZ222695A (en) 1986-11-29 1990-03-27 Ueno Seiyaku Oyo Kenkyujo Kk Synergistic antiviral compositions
BR9207024A (pt) * 1992-01-06 1995-12-05 Pfizer Processo e utilizações para 4,5-DI-hidrogeldanamicina e sua hidroquinona
US5397584A (en) * 1992-12-09 1995-03-14 Mccormick & Company, Inc. Process for preparing stabilized, partially-dehydrated aromatic plant products
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
JP2794342B2 (ja) * 1993-06-29 1998-09-03 ファイザー・インク． 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
EP0833667A4 (en) 1995-06-07 2001-11-21 Univ California STABILIZATION OF POLYNUCLEOTIDE COMPLEXES
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
AU764603B2 (en) 1998-07-17 2003-08-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Water-soluble drugs and methods for their production
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
AU2001271567A1 (en) 2000-06-29 2002-01-14 Trustees Of Boston University Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders
WO2002009696A1 (en) 2000-07-28 2002-02-07 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
EP1373215B1 (en) * 2001-03-30 2006-07-26 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Geldanamycin derivatives useful for treating cancer
AU2002330998A1 (en) 2001-08-06 2003-02-24 Kosan Biosciences, Inc. Benzoquinone ansamycins
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
CA2456175A1 (en) * 2001-08-06 2003-02-20 Kosan Biosciences, Inc. Benzoquinone ansamycins
DE60225307T2 (de) 2001-09-24 2009-03-19 Conforma Therapeutics Corp., San Diego Verfahren zur herstellung von 17-allyl-amino-geldanamycin (17-aag) und anderer ansamycine
US20050074457A1 (en) * 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
CA2474508A1 (en) * 2002-02-08 2003-08-14 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
TW200303363A (en) 2002-02-25 2003-09-01 Upjohn Co Process to prepare and isolate geldanamycin
BRPI0311959B8 (pt) 2002-06-21 2021-05-25 Novo Nordisk Healthcare Ag composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
CN101756961A (zh) 2003-03-13 2010-06-30 康福玛医药公司 含有长链和中链甘油三酯的药物制剂
US20060019941A1 (en) 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
EP2492261B1 (en) 2003-12-23 2015-02-18 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
EP1737825A1 (en) 2004-03-26 2007-01-03 Van Andel Research Institute Geldanamycin and derivatives inhibit cancer invasion and identify novel targets
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
EP1906950A4 (en) 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
CA2613632A1 (en) 2005-06-29 2007-01-04 Shinpei Yamaguchi Benzenoid ansamycin derivative
CN101360492A (zh) 2005-12-01 2009-02-04 康福玛医药公司 含安莎霉素的组合物
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CA2684211A1 (en) 2007-04-12 2008-10-23 Infinity Discovery, Inc. Hydroquinone ansamycin formulations
US9907242B2 (en) 2016-02-18 2018-03-06 Seminis Vegetable Seeds, Inc. Pepper hybrid SV5873HE

Also Published As

Publication number Publication date
BRPI0418147A (pt) 2007-04-17
US20060014731A1 (en) 2006-01-19
CA2547343C (en) 2013-05-14
RU2484086C9 (ru) 2013-08-20
US20090208590A1 (en) 2009-08-20
US20120058982A1 (en) 2012-03-08
US20050288269A1 (en) 2005-12-29
US7361647B2 (en) 2008-04-22
ES2409351T3 (es) 2013-06-26
US7767663B2 (en) 2010-08-03
IL206984A0 (en) 2011-07-31
AU2004309395A1 (en) 2005-07-14
RU2484086C2 (ru) 2013-06-10
IL175911A0 (en) 2006-10-05
JP2011225614A (ja) 2011-11-10
EP2492261A1 (en) 2012-08-29
CN102643233A (zh) 2012-08-22
KR101154351B1 (ko) 2012-06-15
US20090088414A1 (en) 2009-04-02
US7608613B2 (en) 2009-10-27
US7767662B2 (en) 2010-08-03
US20060019939A1 (en) 2006-01-26
CA2547343A1 (en) 2005-07-14
JP2007528875A (ja) 2007-10-18
US20090062250A1 (en) 2009-03-05
US20090209549A1 (en) 2009-08-20
US7375217B2 (en) 2008-05-20
US7833997B2 (en) 2010-11-16
EP1716119A1 (en) 2006-11-02
IL206984A (en) 2015-02-26
US7282493B2 (en) 2007-10-16
PT1716119E (pt) 2013-06-04
WO2005063714A1 (en) 2005-07-14
IL175911A (en) 2012-01-31
US20130203724A1 (en) 2013-08-08
US20090253653A1 (en) 2009-10-08
US20110086110A1 (en) 2011-04-14
NO337933B1 (no) 2016-07-11
US7691840B2 (en) 2010-04-06
US20050227955A1 (en) 2005-10-13
EP2492261B1 (en) 2015-02-18
RU2006126797A (ru) 2008-01-27
US8252779B2 (en) 2012-08-28
AU2004309395C1 (en) 2012-10-04
CN102643233B (zh) 2015-11-25
US7566706B2 (en) 2009-07-28
US7579337B2 (en) 2009-08-25
US8003634B2 (en) 2011-08-23
EP1716119B1 (en) 2013-03-06
JP5313308B2 (ja) 2013-10-09
US20090069280A1 (en) 2009-03-12
US8703755B2 (en) 2014-04-22
JP4869077B2 (ja) 2012-02-01
NO20062707L (no) 2006-09-11
AU2004309395B2 (en) 2011-10-06
KR20060132660A (ko) 2006-12-21
HK1097410A1 (en) 2007-06-22

Similar Documents

Publication Publication Date Title
DK1716119T3 (da) Analoger af benzoquinonholdige ansamyciner til behandling af cancer
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1781604T3 (da) Bis(thio-hydrazid-amid)-salte til behandling af cancere
DK1765391T3 (da) Bakterielle præparater til behandlingen af cancer
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
CY2015003I2 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
IS2935B (is) Misnotkunarvarið lyfjaform til skömmtunar um húð
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK3470535T3 (da) Forudsigelse af sandsynlighed for tilbagevenden af cancer
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1608634T3 (da) Fremgangsmåder til isolering af krystallinsk form af 5-azacytidin
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
DK1755671T3 (da) Terapi af platinresistent cancer
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
IS8125A (is) Kínasólínafleiður til að meðhöndla krabbamein
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
FI20060154L (fi) Neurogeneratiivisten tilojen hoito
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1694122T3 (da) N-arylhydrazonderivater til fröbehandling
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner